Prothena (PRTA)
(Delayed Data from NSDQ)
$23.03 USD
-0.51 (-2.17%)
Updated May 8, 2024 04:00 PM ET
After-Market: $23.05 +0.02 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$23.03 USD
-0.51 (-2.17%)
Updated May 8, 2024 04:00 PM ET
After-Market: $23.05 +0.02 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Zacks News
Acorda Reports Death in Parkinson's Trials, Stock Down 40%
by Zacks Equity Research
Acorda's (ACOR) shares slump significantly after the company complains of safety issues related to a late-stage study on tozadenant, a lead Parkinson's disease candidate.
Prothena (PRTA) Earnings Beat in Q3, Pipeline in Focus
by Zacks Equity Research
Prothena (PRTA) reported a narrower-than-expected loss in the third quarter as the company continued with its pipeline progress.
What's in the Cards for Prothena (PRTA) in Q3 Earnings?
by Zacks Equity Research
Investors focus should remain on pipeline updates when Prothena Corporation (PRTA) reports third-quarter results as it has no approved product in its portfolio.
Prothena's Psoriasis Candidate Disappoints in Phase I Study
by Zacks Equity Research
Prothena Corporation plc (PRTA) announced disappointing results from a phase Ib study of pipeline candidate, PRX003 in psoriasis patients.
AstraZeneca and Takeda Ink Deal to Develop Parkinson's Drug
by Zacks Equity Research
AstraZeneca (AZN) and Takeda Pharmaceutical Company entered into an agreement to jointly develop and commercialize MEDI1341 for the potential treatment of Parkinson's disease.
Prothena (PRTA) Q2 Loss Narrows as Roche Makes $30M Payment
by Zacks Equity Research
Prothena Corporation plc (PRTA) reported a narrower-than-expected loss in the second quarter as the company received a milestone payment from Roche.
Should You Buy Prothena Corporation PLC (PRTA) Ahead of Earnings?
by Zacks Equity Research
Given that Prothena Corporation PLC (PRTA) has a Zacks Rank #3 (Hold) and an ESP in positive territory, investors might want to consider this stock ahead of earnings.
Can Prothena (PRTA) Deliver a Beat this Earnings Season?
by Zacks Equity Research
Prothena Corporation plc (PRTA) is expected to report second-quarter results next week and we expect investor focus on pipeline updates.
Prothena (PRTA) Down 5.8% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena (PRTA) Q1 Loss Narrower than Expected, Updates View
by Zacks Equity Research
Prothena Corporation plc (PRTA) reported a loss of 99 cents per share in the first quarter of 2017, wider than the year-ago loss of 81 cents.
What to Expect from Prothena (PRTA) This Earnings Season?
by Zacks Equity Research
Prothena Corporation plc (PRTA) is expected to report first-quarter 2017 results early next month.
Why Is Prothena (PRTA) Up 4.5% Since the Last Earnings Report?
by Zacks Equity Research
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena (PRTA) Reports Wider-than-Expected Loss in Q4
by Zacks Equity Research
Prothena's wider-than-expected loss in the fourth quarter was disappointing.
The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences
Can Prothena (PRTA) Pull a Surprise This Earnings Season?
by Zacks Equity Research
Prothena Corporation plc (PRTA) is scheduled to report fourth-quarter 2016 results on Feb 14 after the market closes.